The amniotic membrane has long been applied for wound healing and treatment of ophthalmological disorders, even though the mechanisms underlying its actions remain to be clarified. Recently, cells derived from fetal membranes of human term placenta have raised strong interest in regenerative medicine for their stem cell potential and immunomodulatory features. Our study aimed to investigate the possible utility of amniotic membrane to limit postischemic cardiac injury. A fragment of human amniotic membrane was applied onto the left ventricle of rats that had undergone ischemia through left anterior descending coronary artery ligation. Echocardiographic assessment of morphological and functional cardiac parameters was then performed over a 3-month period. We demonstrated that application of an amniotic membrane fragment onto ischemic rat hearts could significantly reduce postischemic cardiac dysfunction. The amniotic membrane-treated rats showed higher preservation of cardiac dimensions and improved cardiac contractile function in terms of higher left ventricle ejection fraction, fractional shortening, and wall thickening. These improvements were apparent by day 7 after application of the amniotic membrane, persisted for at least 2 months, and occurred independently of cardiac injury severity. No engraftment of amniotic cells was detected into host cardiac tissues. Our results suggest that use of amniotic membrane may constitute a convenient vehicle for supplying cells that produce cardioprotective soluble factors, and reinforce the notion that this tissue constitutes a cell source with clinical potential that has yet to be completely revealed.
INTRODUCTION
mal cells derived from the bone marrow (11, 23, 47, 52) as well as for adipose tissue-derived cells (13, 29, 54) . In parallel, a variety of cell types, including fetal Myocardial infarction causes an irreversible loss of cardiomyocytes, which, together with the inability of re-cardiomyocytes (37) , skeletal myoblasts (10, 17) , resident myocardial progenitors (6) , bone marrow cells (34, maining tissue cells to adequately compensate for the injury, results in impaired cardiac function and possible 48), adipose tissue-derived cells (29) , and umbilical cord blood cells (19, 30) , have been applied in preclinical heart failure.
In the last decade, a number of studies have been studies aimed at investigating the efficacy of these cells in cardiac repair. performed both in animal models and in clinical trials to assess if and to what extent cell therapy may be benefi-Interestingly, most groups have reported that cell therapy can improve postischemic cardiac function, although cial in repairing infarcted hearts (31, 36) . The obvious primary intent of cell therapy would be to regenerate such effects do not appear to be associated with cardiac differentiation of the transplanted cells. Therefore, the the injured myocardium, and several studies have been undertaken in order to investigate the ability of adult current predominant hypothesis regarding the mechanism underlying these beneficial effects is that, rather than re-stem cells to differentiate into cells with cardiomyocytelike features. Although the results obtained are still sub-generation of the damaged myocardial tissue, progenitor and stem cells promote repair of heart injury through par-ject to debate, some authors have demonstrated cardiomyogenic differentiation potential for mesenchymal stro-acrine secretion of growth and survival factors that induce neovascularization (18), reduce scar formation, and im-tested the number and viability of cells in amniotic membranes which had been stored for 24 h as described, prove myocardial contractility (14, 36) .
Among the different types of cells with potential clin-observing that these parameters were not significantly reduced compared to those that were seen using fresh ical applicability for cell therapy, fetal stem cells have recently gained particular interest in the field of cell membrane (unpublished data). transplantation and regenerative medicine for several important reasons, including their low immunogenicity, Myocardial Infarction Model which has been demonstrated through both in in vitro
All animal experiments were carried out in accor- (21, 22) and in vivo studies (2, 26, 55) , as well as for their dance with current Italian and European regulations and ability to engraft in allogeneic and xenogeneic hosts laws on the Use and Care of Animals for research (DL. (2, 5, 25) . Preclinical studies have shown that transplanta-116/27 January 1992). tion of xenogeneic and allogeneic fetal membrane-derived Seventy-seven male Sprague-Dawley rats were ancells results in a reduction in bleomycin-induced lung aesthetized with isoflurane and, after lateral thoracotomy fibrosis in a mouse model (4) and improvement of spinal and heart exteriorization, left ventricle infarction was incord injury in monkeys (39), while potential applications duced by permanent ligation of the left anterior descendfor these cells have also been suggested for ischemic ing (LAD) artery at 1 mm from the atrioventricular stroke (53) and treatment of liver diseases (27, 38, 46) . groove. Ischemia induction was confirmed by a paling Furthermore, placental fetal membrane-and amniotic in epicardial color and dyskinesis. The heart was then fluid-derived cells have progenitor/stem cell potential repositioned into the thorax. (7, 35) and, even though their ability to differentiate to-For animals in the amnion treatment group, immediward cardiomyocytes is still debated (40, 50, 55) , a promately after LAD ligation, an amniotic membrane fragising study by Ventura et al. (50) has recently reported ment was gently placed onto the left ventricle with its improved myocardial function after transplantation of mesenchymal side in contact with the epicardial surface. fetal membrane-derived cells into infarcted rat hearts.
In order to fasten the amniotic membrane fragment to On the other hand, amniotic membrane patches have the heart, the excess suture that was left uncut after LAD long been applied in ophthalmology and wound healing artery ligation was passed around an edge of the amnidue to their anti-inflammatory and antiscarring properotic membrane fragment and tightened ( Fig. 1A ). Fities (9) . nally, the amniotic membrane fragment was laid flat Therefore, considering that amniotic membrane upon the ventricle surface ( Fig. 1B) . The amniotic mempatches could act both as a source of fetal stem cells and brane fragment was therefore applied to the ventricle as a vehicle for local cell delivery to ischemic areas, surface without any direct suture on the heart. The mothus avoiding the risks of intramyocardial cell inoculadality that was used to keep the membrane fragment lytion (12), we have hypothesized that their use after myoing in place on the ventricle was to tie one of the edges cardial infarction could represent a potential new stratof the membrane at the point of coronary ligation using egy for treatment of ischemic injuries. the suture thread that had been used for the ligation it-In this study, we demonstrate that application of amself, as represented in Figure 1 . Therefore, the memniotic membrane fragments to infarcted rat hearts signifbrane fragment was only made to lie on the left ventricle icantly reduces postischemic cardiac dimensional alterwithout any artificial reinforcing effect. After this proceations and improves myocardial function for up to at dure was performed, the sternum and the skin incisions least 60 days after ischemia induction.
were sutured. Each rat was given perioperatory analgesia and antibiotics after surgery.
MATERIALS AND METHODS

Amniotic Membrane
Experimental Groups Human term placentas were obtained with maternal consent according to the guidelines of the Ethical Com-After surgery, the ischemic rats were randomly assigned to two experimental groups: Ischemia group (in-mittee of the Catholic Hospital (CEIOC). The amnion was immediately peeled from the chorion and washed farcted rats that received no treatment) and Ischemia + amnion group (infarcted rats in which amniotic membrane extensively in phosphate-buffered saline containing 100 U/ml penicillin and 100 µg/ml streptomycin. The am-was applied to the ventricle surface). A group of untreated noninfarcted rats (n = 8) served as normal con-nion was then cut into 5 × 5-cm fragments, which were stored separately at room temperature, as reported by trols. Another group of noninfarcted rats (n = 4) was treated with amniotic membrane fragments to allow as-Hennerbichler et al. (15), in 50-ml vials filled with serum-and phenol red-free DMEM in sterile conditions. sessment of any effects of the membrane on nonischemic hearts. The amniotic fragments were used within 24 h. We had Figure 1 . Application of an amniotic membrane fragment onto the cardiac ischemic surface. After being placed gently onto a plastic spatula, the amniotic fragment was fastened to the heart using the suture that had been left uncut after LAD artery ligation. The suture was passed around an edge of the amniotic fragment and tightened (A). Next, the amniotic fragment was laid flat upon the ventricle surface with its mesenchymal side in contact with the epicardial surface (B).
Echocardiography
length and the respective diameter), and stroke volume. The mitral diastolic filling pattern was also analyzed. Seven days after surgery, a complete echocardiogra-Heart rate was measured by a single channel electrocarphy study (B Mode, M Mode, Doppler, Color Doppler) diogram and/or by calculating the interval between two was performed in the 52 surviving rats using MyLab 30 subsequent cardiac cycles at pulsed Doppler. CV apparatus (Esaote, Genova, Italy) equipped with a phased array 10-5 MHz probe. Infarct size was esti-Scar Size Assessment mated as the percentage of the myocardial akinetic area Scar sizes were assessed in ischemic untreated and corrected for left ventricle endocardial circumference, amnion-treated rats at 30 and 90 days after ischemia inmonitored on a midventricular short axis in diastole, as duction. After euthanasia, the hearts were excised and reported by Sakakibara et al. (37) . Rats showing detecteach scar size determined as a percentage of the entire able left ventricle akinetic areas (n = 30) continued to be left ventricle area, as reported by Nagaya et al. (32) . monitored by echocardiography at 30, 60, and 90 days after LAD artery ligation.
Assessment of Amniotic Cell Engraftment in Rat Echocardiographic measurements were performed
Cardiac Tissues under mild anesthesia (induced with an intramuscular Immunohistochemistry. Immunohistochemical studies injection of 10 mg/kg xylazine and 50 mg/kg ketamine) were performed on formalin-fixed and paraffin-embedand executed under continuous ECG monitoring by a ded tissue sections using the Vector M.O.M. Immunoblinded operator in accordance with the guidelines of detection kit (Vector, Burlingame, CA). To detect the the American Society of Echocardiography (41) and folpresence of human amniotic cells, samples were immulowing previously described procedures (51) .
nostained with monoclonal antibodies specific for hu-For each rat, the following measurements were perman cytokeratin 19 (CK 19, Ab-4) (clone BA17) diluted formed: complete left ventricle M Mode, EPSS (E Point 1:50 and vimentin (clone 3B4) diluted 1:100. The pri-Septal Separation), and left ventricle B Mode evaluation mary antibody was applied for 1 h at room temperature. (area-long axis method), aortic annulus and root, left Novared (Vector) was used as the chromogen, and heatrium diameter, aortic and mitral flow determination. matoxylin for counterstaining. On the basis of these measurements, the following parameters were calculated: fractional shortening, ejection PCR Analysis. Total DNA (50-100 ng) was extracted from heart tissue using a Bio robot EZ1 (Qiagen, fraction, septal and parietal thickening, systolic and diastolic sphericity index (the ratio between left ventricle Hilden, Germany) and the EZ1 Tissue Kit (Qiagen) ac-cording to the manufacturer's instructions, and was then rats fit this criterium, with akinetic areas ranging from 11.4% to 36.1%. Of these, 14 belonged to the Ischemia amplified in 50-µl reactions containing dNTPs (200 µmol) and GoTaq DNA polymerase reagents (Promega, group and 16 to the Ischemia + amnion group. Rats from both groups showed cardiac akinetic areas that were not Madison, WI, USA) and the following primers (25 pmol) specific for the human sequence of the cyto-statistically different (19.83 ± 2.41% vs. 19 .88 ± 2.27%, respectively). Two late deaths occurred: one in the Is-chrome B mitochondrial gene: 5′-CCCATACATTGG GACAGACC-3′ (forward); 5′-GACGGATCGGAGAA chemia group at day 60 and one in Ischemia + amnion group at day 89 after LAD artery ligation. TTGTGT-3′ (reverse) (43) . All PCR reactions included an initial step at 95°C for 10 min. This was followed by
In order to demonstrate the reliability of the echocardiographically determined cardiac akinetic area as an in-40 cycles (94°C for 30 s, 58°C for 30 s, 72°C for 1 min) for DNA amplification of human mitochondrial cyto-dex of the severity of the induced ischemia, the correlation between the akinetic areas measured at day 7 and chrome B. PCR products were analyzed by agarose gel electrophoresis and ethidium bromide staining, followed the scar sizes measured post mortem 90 days after LAD artery ligation was assessed in rats from the Ischemia by Southern blotting. For Southern blot analysis, PCR products were transferred to nylon membranes (Hybond group. The calculated correlation coefficient of 0.75 (95% CI: 0.33-0.92) confirmed the validity of the ap-N+, Amersham Biosciences, Little Chalfont, UK) and hybridized to specific probes labeled with horseradish proach, in line with previously reported data (28) . According to Sakakibara et al. (37) , the echocardio-peroxidase enzyme (ECL Gold, Amersham Biosciences). Chemiluminescent signals were detected with a Gel Doc graphically evaluated cardiac akinetic areas were used both to select rats to be included in the study, as well as 2000 system (Bio-Rad, Hercules, CA).
to classify the severity of the ischemic injury induced in Statistical Analysis those rats. The echocardiographic and infarct size measurements Indeed, according to the hypothesis that the effect of are expressed as means ± SE. The effect of treatment treatment might vary in relation to different degrees of and time on the echocardiographic outcomes was asischemic injury, and that the degree of injury could afsessed by a repeated measures analysis of variance via fect the echocardiographic parameter values per se, we linear mixed effects models. Treatment and time were chose to include the severity of the induced ischemia in included as fixed effects while subjects were treated as the statistical analysis in order to adjust the model fitted random effect to take into account correlation among to the data (as reported in Statistical Analysis, see Matemeasures on the same rats. All models were adjusted for rials and Methods). Based on the echocardiographic the severity of the induced ischemic damage to control analyses performed at day 7, animals were classified as for a possible confounding effect. A treatment group by follows: i) mild ischemia (akinetic area ranging from time interaction term was tested to investigate possible 10% to 15%); ii) moderate ischemia (15-20%), and iii) time effect on treatment. A treatment group by severity severe ischemia (>20%). As a result of this classificainteraction term was tested in order to evaluate if treattion, the rats belonging to the Ischemia and Ischemia + ment effect could change across severity of differing amnion groups were assigned to injury categories as regrade. The differences among groups with regard to scar ported in Table 1 . sizes were assessed by Student's t-test. Values of p < Effects of Amniotic Membrane on Ischemia-Induced 0.05 were considered to indicate statistical significance.
Cardiac Dimensional Changes A correlation coefficient with respective 95% confidence interval (CI) was estimated to assess the relation-Cardiac dimensions were evaluated in all rats, ischeship between akinetic areas measured at day 7 and the mic or not, amnion-treated or untreated, at four time scar sizes measured 90 days after LAD ligation. All statistical analyses were performed using the R software which died within 24 h following surgery. In order to Moderate ischemia 6 5 11 ensure the presence of a myocardial defect in the surviv-Severe ischemia 4 6 10 ing animals, we selected those rats that showed a detect- . 3B) ; and a diastolic deficit in terms of alterations in the pattern of mitral inflow, ventricle diameters and lengths ( Fig. 2A , B, Table 2 ); low systolic and diastolic sphericity indexes, indicating detected as increments in the early filling velocity (E velocity) ( Table 2 ) and in the ratio of early to late filling that ischemic ventricles displayed more spherical shapes than those of control hearts (Fig. 2C, D) ; thin left ventri-velocities (E/A) ( Fig. 3D ). In particular, except for some rats at day 90, E/A measurements in control rats never cle walls were associated with ischemic areas (Fig. 2E , F), indicative of loss of ventricle muscle in these areas;
exceeded the value of 2.0, which has been proposed by some authors as a threshold value for restrictive pattern high values of E point septal separation (Fig. 2G ), indicative of increased left ventricle cavities and reduced mi-occurrence (28) . On the contrary, Ischemia group rats showed E/A values over this threshold at days 7, 30, tral inflow; and high left atrium diameters ( Fig. 2H) . No changes were observed in the interventricular septum and 60, with some rats also showing higher values at day 90. (IVS) thickness ( Table 2) .
Application of a fragment of amniotic membrane In our study, and in agreement with findings reported by others (20), the stroke volume in Ischemia group rats onto the cardiac ischemic injury resulted in better preservation of cardiac dimensions with respect to untreated was similar to that calculated for control rats (Fig. 3C ). Application of amniotic membrane was able to pre-ischemic rats. Compared to the Ischemia group, the Ischemia + amnion group showed significantly lower sys-serve myocardial function and, indeed, left ventricular fractional shortening (FS%) and ejection fraction (EF%) tolic left ventricle diameters (p < 0.05) ( Fig. 2A) ; higher systolic left ventricle sphericity indexes (p < 0.01 at day in Ischemia + amnion group rats were higher than those recorded in Ischemia group rats at days 7 and 60 (p < 60) (Fig. 2C) ; and markedly higher left ventricle wall thickness values, either measured in systole (p < 0.05) 0.01) (Fig. 3A, B) . At day 30, the differences observed between Ischemia + amnion and Ischemia groups for FS% ( Fig. 2E ) or in diastole (p < 0.05) (Fig. 2F) . The Ischemia + amnion group also showed lower EPSS (p < 0.05) and EF% were marked, although they did not reach statistical significance (p = 0.06 and p = 0.09, respectively). (Fig. 2G ) and lower left atrium diameters (p < 0.05) ( Fig. 2H ). Treatment with amniotic membrane did not
In agreement with the better systolic function detected in Ischemia + amnion group rats, higher thicken-result in any statistically significant effects on left ventricle diameters and sphericity indexes measured in dias-ing values of left ventricle wall were also observed in this group (Table 2) . Moreover, even though no worsen-tole ( Fig. 2B, D) .
Effects of amniotic membrane on cardiac ischemia-ing in stroke volume was observed in the Ischemia group, the values of stroke volume calculated in the induced dimensional changes were already evident at the first echocardiographic monitoring performed 7 days after treated rats were higher than those observed in the Ischemia group except for 90 days after LAD artery ligation ischemia induction, and were maintained up to day 60. However, at day 90, no appreciable differences were re-( Fig. 3C) . Interestingly, at days 7, 30 and 60, Ischemia + amnion corded among Ischemia and Ischemia + amnion groups. Interestingly, treatment with amniotic membrane resulted group rats showed lower values for the ratio of early to late mitral filling velocities (E/A ratio) compared to in beneficial effects on cardiac ischemia-induced dimensional changes, and these effects were not influenced by Ischemia group rats, although these differences were not statistically significant. At days 30 and 60, E/A values injury severity of different degrees.
In order to explore whether amniotic membrane exceeding the threshold value of 2.0 were more frequently detected in Ischemia group rats (in 6/14 rats, or could exert effects independently of ischemia induction, amniotic membrane fragments were also applied to the 42.9%) with respect to in Ischemia + amnion group rats (in 3/16 rats, or 18.8%) ( Fig. 3D , Table 2 ). As also re-left ventricle surface of non ischemic rats (n = 4). Compared to healthy controls, these rats showed no apprecia-ported by other authors, we detected the highest E/A values in rats with severe ischemia, indicating the occur-ble changes at any time points in the echocardiographically evaluated dimensional parameters (data not shown).
rence of severe diastolic dysfunction (20,28). The higher degree of preservation of hemodynamic Effects of Amniotic Membrane on Ischemia-Induced conditions in amniotic membrane-treated rats was also Left Ventricle Dysfunctions confirmed indirectly by the lower heart rate values recorded at days 7 and 30, in these rats, compared to Is-The infarct produced a rapid myocardial functional failure that was characterized by both a systolic deficit, chemia group rats (p < 0.05) (Table 2) , which, during the first month, developed a transient compensatory as shown by a decline in left ventricle fractional shortening (from 35.5 ± 1.6% to 23.8 ± 2.4% in control and in tachycardia. As observed for cardiac dimensional changes, treat-Effects on Ischemia-Induced Myocardial Scarring ment with amniotic membrane also provided early beneficial effects on ischemia-induced cardiac functional im-Scar sizes in untreated and amniotic membranetreated ischemic rats were assessed at two different time pairment irrespective of the different degrees of the ischemic injury induced. The better fractional shortening points (30 and 90 days) after injury induction. Rats euthanized 30 days after ischemia induction (n = 14; 7 in and ejection fraction values were measured just 7 days after amniotic membrane application. However, by day Ischemia group and 7 in Ischemia + amnion group) belonged to a separate experimental set to that described 90, myocardial systolic function was similar in Ischemia + amnion and Ischemia groups.
above in which all animals were assessed for echocardiographic parameters and euthanized at day 90. No cardiac dysfunctions were observed at any time points when amniotic membrane fragments were applied At 30 days from ischemia induction, amniotic membrane-treated rats showed scar sizes significantly smaller onto ventricle surfaces of non ischemic rats (data not shown).
than those of ischemic untreated rats (p < 0.05) ( Fig. 
DISCUSSION
This study demonstrates that, when applied to a myocardial ischemic surface, amniotic membrane has protective effects against deleterious ischemia-induced changes in cardiac contractile function and dimensions. Our study combines the advantages of a well-established and commonly applied cardiac ischemia model (LAD artery ligation performed in rats) with echocardiographic analysis, which allows reliable measurement of ischemia-induced morphological and functional cardiac alterations (1, 20, 28, 51) . Furthermore, given that this procedure is noninvasive, it allows repeated measurements to be taken for each animal over several time points.
Previous studies performed in both preclinical cardiac ischemia models and in patients suffering from ischemic diseases (31, 36) have so far been aimed at investigating the efficacy of cell therapy on cardiac repair by using different cell types including bone marrowderived cells (16, 32, 34, 42, 48, 49) , skeletal myoblasts (10), fetal cardiomyocytes (37) , and endothelial progenitor cells (56) . Interestingly, it has recently been shown that transplantation of placental fetal membrane-derived cells into ischemic rat hearts results in a reduction in cardiac scar size as well as an improvement in cardiac contractile function with less reduction of left ventricle wall thickness, when assessed 28 days after cell treatment (50). faces in order to explore the potential efficacy of this The rats that were euthanized at day 30 after ischemia induction belonged to an experimental set from a separate study. tissue as a possible treatment for ischemic diseases. We
The number of rats in each experimental group is indicated in have studied the effects of amniotic membrane in this the bars. Statistical significance was assessed by Student's tmodel for a prolonged period and have classified the test between Ischemia and Ischemia + amnion groups (each different levels of severity of cardiac injury induced by analysis was performed between groups of the same experi-LAD artery ligation, to allow evaluation of the effects mental set). of amniotic membrane on dimensional and functional cardiac alterations of different degrees (mild, moderate, and severe).
Our results show that treatment of ischemic rats with amniotic membrane plays a major role in preserving 4A). At 90 days, as expected, based on the decline in myocardial contractile function. In fact, the echochardiobserved effects of amniotic membrane on the echocarographic left ventricle functional parameters and mordiographic parameters, scar extensions in the Ischemia phological measures, assessed during systole, were pre-+ amnion group rats were not statistically different from served to a significantly higher degree compared to those measured in Ischemia group rats (Fig. 4B) . untreated ischemic rats. In addition, amniotic patching resulted in absence of compensatory tachycardia.
Amniotic Cell Engraftment
Treatment with amniotic membrane not only improved the systolic function of ischemic rats, but also Cell engraftment was evaluated in host cardiac tissues by immunohistochemistry and PCR analysis after resulted in some positive effects on the cardiac diastolic function, as demonstrated by the better diastolic filling 30 and 90 days from amniotic membrane application. No cell engraftment was observed at either time point parameters (E/A ratio and EPSS) and the lower dilation of the left atrium recorded in these treated animals. (data not shown).
Beneficial cardiac effects resulting from application
Therefore, amniotic cells may act via a paracrine mechanism, as reported for other cells that have been applied of amniotic membrane were already apparent by day 7 when the first echocardiography examination was per-in cell therapy approaches and that have been shown to counteract cardiac injury by releasing mediators that formed. This is in agreement with previous studies where cell therapy was applied in cardiac ischemia mod-influence the survival, differentiation, and proliferation of host tissue cells (10, 14) . els using other cell types such as bone marrow-derived cells (12,33) and skeletal muscle cells (10) . The majority It is also interesting to note that, besides the factors mentioned above, the amniotic membrane also expresses of these previous studies report assessment of cardiac parameters for up to 30 days after cell therapy treatment;
high levels of thymosin-β4 (data not shown), a short peptide that has been demonstrated to accelerate wound instead, we have performed cardiac evaluations until day 90 and observed that amniotic membrane patching ex-healing (24) and, more recently, has also been shown to protect the murine heart against ischemic injury when erts benefits on ischemia-induced cardiac functional and dimensional alterations until day 60. The echocardiogra-administered exogenously (3). It is very likely that more than one of the factors phy evaluations performed at day 90 revealed no differences between amniotic membrane-treated and untreated mentioned above may play a role in amniotic membrane-mediated preservation of ischemic myocardial ischemic rats, except for left ventricle wall thickness, which remained significantly higher in amniotic mem-function, and it is therefore tempting to hypothesize that amniotic membrane patches may be useful as sources brane-treated rats up until the last echo-analysis. These data could suggest that further application of amniotic for release of soluble factors. The amniotic membrane could represent a very interesting alternative to cell membrane may be required to prolong the cardiac benefits.
sheets and cardiac cell patches, which have recently been proposed as an innovative local cell delivery sys-Interestingly, our data have also demonstrated that cardiac protection resulting from application of amniotic tem for assuring homogeneous distribution of transplanted cells onto the myocardial ischemic area (29, 42) . membrane is independent of the severity of the injury induced by LAD artery ligation, and it is therefore In addition, the use of the amniotic membrane patching may also prolong the survival of the transplanted cells, tempting to speculate that amniotic membrane could have beneficial effects on a wide spectrum of ischemic given that the cells are embedded in a collagen-rich stromal matrix, which may preserve their integrity by pre-pathology severities.
In this study, we also explored the possible mecha-venting direct contact with ischemic and necrotic cardiac tissues that may otherwise accelerate their death. nisms through which the amniotic membrane may exert beneficial effects on ischemic rats. Firstly, we consid-Finally, but not of secondary importance, the use of amniotic membrane as a treatment for myocardial ische-ered the possibility that these effects could have been due to the engraftment of cells derived from the human mic diseases offers the evident advantages of being in plentiful supply and being applicable immediately with-amniotic membrane into the host tissues. The fact that we were unable to detect human cells in rat cardiac tis-out the need for any cell isolation, selection, or culture steps, which makes it a low-cost approach; in addition, sues at 1 and 3 months after application of the amniotic membrane (data not shown) suggests that engraftment amniotic membrane has good preservability (15) and is immunologically tolerated in both allogeneic and xeno-of amniotic cells was either absent or very low. Therefore, it is very likely that the effects observed were in-geneic conditions, both in vitro (21) and in vivo (2). These considerations, together with our experimental stead associated with the release of soluble factors by cells of the amniotic membrane, which we have recently findings, suggest that application of amniotic membranes for wound healing could be extended to cardiac ische-hypothesized as the mechanism by which placenta-derived cells may also work to reduce bleomycin-induced lung mic injuries.
In conclusion, the application of amniotic membrane fibrosis (4) . It has been reported that amniotic membrane, as well as cells derived from this tissue, are able onto the ischemic region of the left ventricle is able to limit myocardial dimensional alterations and contractile to release cytokines that have potent immunomodulatory and anti-inflammatory effects, such as interleukin-10 dysfunction in a rat model of myocardial infarction. These effects are already evident 7 days after application and interleukin-6 (8). Furthermore, amniotic cells have also been reported to release growth factors associated of the amniotic membrane, persist for at least 2 months, and are independent of the severity of the induced car-with wound healing, including angiogenetic factors [vascular endothelial growth factor, angiogenin and diac injury. The benefits conferred by treatment with amniotic membrane do not seem to be related to the platelet-derived growth factor (44)], as well as cell proliferation [i.e., epidermal, keratinocyte, hepatocyte, and engraftment of human amniotic cells into the ischemic rat hearts, but they are likely due to release of soluble basic fibroblast growth factors (45) ] and differentiation [i.e., transforming growth factors β1, β2, and β3 (44)].
factors that may modulate the ischemic inflammatory 
